Safety Gaps in Health: IIT Students Propose AI-Driven Solutions
In a groundbreaking initiative, students from various Indian Institutes of Technology (IITs) and other engineering colleges have proposed innovative AI-driven solutions to address significant regulatory and safety gaps in drug development and monitoring. This initiative is part of Novartis India’s NEST 2.0 program, which aims to nurture excellence and strengthen talent in the healthcare sector.
Overview of the Initiative
The NEST 2.0 initiative, spearheaded by the Novartis Development Hub in India, has brought together talented young minds from institutions such as IIT Patna, Gokaraju Rangaraju Institute of Engineering and Technology, IIT Bombay, and Vishwakarma Institute of Technology, Pune. These students have been tasked with finding solutions to longstanding challenges in the pharmaceutical industry.
Key Participants and Their Proposals
Among the teams participating in this initiative, two standout proposals have emerged:
- Team Codeies from Vishwakarma Institute of Technology, Pune
- Team NovaNexus from IIT Patna
Team Codeies: Enhancing Pharmacovigilance
Team Codeies tackled a critical issue in pharmacovigilance: the incomplete reporting of drug side effects. When patients report adverse reactions, pharmaceutical companies are required to collect detailed information to assess risks and comply with global safety regulations. However, initial reports are often lacking in detail.
The traditional follow-up methods, which involve repeated phone calls, emails, and lengthy questionnaires, often fall short due to various challenges. These include:
- Busy schedules of doctors and patients
- Fatigue from repeated follow-ups
- Language barriers
- Mistrust stemming from spam or scam communications
To address these challenges, Team Codeies developed SmartFU, an AI-driven digital follow-up platform. SmartFU automatically identifies missing safety information in reports and generates targeted, relevant follow-up questions instead of lengthy generic forms. This platform prioritizes high-risk cases, customizes communication based on whether the reporter is a doctor or a patient, and selects the most suitable communication channel, such as email or SMS.
Team NovaNexus: The Composite Weighted Mass Balance Framework
Team NovaNexus focused on the complexities of forced degradation testing, a process where medicines are exposed to heat, light, and humidity to study their breakdown. In this context, scientists calculate mass balance to ensure that the total amount of the drug and its breakdown products are accounted for correctly.
However, there are significant challenges in this area. Analytical instruments may not always detect every breakdown product, leading to discrepancies in results. Some substances may fall below detection limits, and variations in detector responses can complicate the analysis. When results do not add up neatly, companies face difficulties in determining whether the issue is a genuine chemical problem or simply a limitation of the testing method, often resulting in delays and repeated experiments.
To overcome these challenges, Team NovaNexus proposed the Composite Weighted Mass Balance (CWMB) Framework. This framework evaluates the reliability of the testing method before interpreting results. It assigns confidence weights based on various factors, including:
- Assay reliability
- Detection limits
- Chromatographic performance
- Detector response differences
By implementing this framework, companies can better assess the reliability of their testing methods, leading to more accurate interpretations of results and ultimately enhancing the drug development process.
Impact and Future Directions
Sadhna Joglekar, head of the Novartis Development Hub in India, expressed enthusiasm about the students’ innovative approaches. She remarked, “We were encouraged by how naturally these young minds integrated technology and AI into their solutions. The focus now is on evaluating whether these ideas have the potential to deliver meaningful and scalable impact for the real world.”
The proposals from these talented students highlight the potential of AI in transforming the pharmaceutical industry. By addressing critical gaps in safety and regulatory compliance, these solutions could lead to improved patient outcomes and more efficient drug development processes.
Conclusion
The innovative AI-driven solutions proposed by students from IITs and other engineering institutions represent a significant step forward in addressing safety gaps in health. As the pharmaceutical industry continues to evolve, the integration of technology and artificial intelligence will play a crucial role in enhancing drug safety and efficacy.
Note: The information presented in this article is based on the initiative led by Novartis India’s NEST 2.0 program and reflects the proposals made by participating teams.
